1.69 USD
+0.01 (+0.6%)
Overall IMCC gets a fundamental rating of 3 out of 10. We evaluated IMCC against 191 industry peers in the Pharmaceuticals industry. IMCC has a bad profitability rating. Also its financial health evaluation is rather negative. IMCC is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IMCC has reported negative net income.
IMCC had a positive operating cash flow in the past year.
In the past 5 years IMCC always reported negative net income.
In the past 5 years IMCC always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -10.43%, IMCC is doing good in the industry, outperforming 65.97% of the companies in the same industry.
IMCC's Return On Equity of -88.04% is in line compared to the rest of the industry. IMCC outperforms 41.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.43% | ||
| ROE | -88.04% | ||
| ROIC | N/A |
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IMCC has a Gross Margin (18.58%) which is comparable to the rest of the industry.
IMCC's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for IMCC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
2. Health
2.1 Basic Checks
IMCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMCC has been increased compared to 1 year ago.
Compared to 5 years ago, IMCC has more shares outstanding
IMCC has a worse debt/assets ratio than last year.
2.2 Solvency
IMCC has an Altman-Z score of -7.25. This is a bad value and indicates that IMCC is not financially healthy and even has some risk of bankruptcy.
IMCC has a worse Altman-Z score (-7.25) than 66.49% of its industry peers.
IMCC has a debt to FCF ratio of 4.09. This is a neutral value as IMCC would need 4.09 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.09, IMCC belongs to the best of the industry, outperforming 84.29% of the companies in the same industry.
A Debt/Equity ratio of 2.52 is on the high side and indicates that IMCC has dependencies on debt financing.
IMCC has a worse Debt to Equity ratio (2.52) than 80.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.52 | ||
| Debt/FCF | 4.09 | ||
| Altman-Z | -7.25 |
ROIC/WACCN/A
WACC11.72%
2.3 Liquidity
A Current Ratio of 0.72 indicates that IMCC may have some problems paying its short term obligations.
IMCC has a Current ratio of 0.72. This is amonst the worse of the industry: IMCC underperforms 90.05% of its industry peers.
A Quick Ratio of 0.59 indicates that IMCC may have some problems paying its short term obligations.
IMCC has a Quick ratio of 0.59. This is amonst the worse of the industry: IMCC underperforms 87.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.59 |
3. Growth
3.1 Past
The earnings per share for IMCC have decreased strongly by -78.84% in the last year.
Looking at the last year, IMCC shows a quite strong growth in Revenue. The Revenue has grown by 10.71% in the last year.
The Revenue has been growing by 16.64% on average over the past years. This is quite good.
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
3.2 Future
Based on estimates for the next years, IMCC will show a very strong growth in Earnings Per Share. The EPS will grow by 36.54% on average per year.
Based on estimates for the next years, IMCC will show a very strong growth in Revenue. The Revenue will grow by 26.24% on average per year.
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IMCC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, IMCC is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.18 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IMCC's earnings are expected to grow with 36.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.54%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for IMCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:IMCC (12/11/2025, 12:39:19 PM)
1.69
+0.01 (+0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners18.37%
Inst Owner Change320.06%
Ins Owners41.71%
Ins Owner ChangeN/A
Market Cap8.87M
Revenue(TTM)54.03M
Net Income(TTM)-4.69M
Analysts82.86
Price TargetN/A
Short Float %2.96%
Short Ratio0.15
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-17.69%
Min Revenue beat(2)-25.65%
Max Revenue beat(2)-9.73%
Revenue beat(4)1
Avg Revenue beat(4)-9.56%
Min Revenue beat(4)-25.65%
Max Revenue beat(4)9.9%
Revenue beat(8)3
Avg Revenue beat(8)-4.84%
Revenue beat(12)3
Avg Revenue beat(12)-9.88%
Revenue beat(16)5
Avg Revenue beat(16)-5.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.23 | ||
| P/FCF | 3.18 | ||
| P/OCF | 3.06 | ||
| P/B | 2.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)0.53
FCFY31.43%
OCF(TTM)0.55
OCFY32.68%
SpS7.49
BVpS0.73
TBVpS-0.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.43% | ||
| ROE | -88.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 18.58% | ||
| FCFM | 7.09% |
ROA(3y)-119.26%
ROA(5y)-87.85%
ROE(3y)-367.14%
ROE(5y)-273.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y497.26%
GM growth 5YN/A
F-Score7
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.52 | ||
| Debt/FCF | 4.09 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.98% | ||
| Cap/Sales | 0.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.72 | ||
| Quick Ratio | 0.59 | ||
| Altman-Z | -7.25 |
F-Score7
WACC11.72%
ROIC/WACCN/A
Cap/Depr(3y)15.95%
Cap/Depr(5y)83.89%
Cap/Sales(3y)1.45%
Cap/Sales(5y)6.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.09%
EPS Next Y86.24%
EPS Next 2Y36.54%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)10.71%
Revenue growth 3Y16.64%
Revenue growth 5YN/A
Sales Q2Q%-14.29%
Revenue Next Year41.23%
Revenue Next 2Y26.24%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y66.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.87%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y136.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y143.37%
OCF growth 3YN/A
OCF growth 5YN/A
IM CANNABIS CORP / IMCC FAQ
What is the fundamental rating for IMCC stock?
ChartMill assigns a fundamental rating of 3 / 10 to IMCC.
What is the valuation status for IMCC stock?
ChartMill assigns a valuation rating of 2 / 10 to IM CANNABIS CORP (IMCC). This can be considered as Overvalued.
Can you provide the profitability details for IM CANNABIS CORP?
IM CANNABIS CORP (IMCC) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for IMCC stock?
The Earnings per Share (EPS) of IM CANNABIS CORP (IMCC) is expected to grow by 86.24% in the next year.